BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ranolazine readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ranolazine\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06570473-8659@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Ranolazine: Phase 2 readout est. (NCT06570473)
DESCRIPTION:Ranolazine\, phase 2.\nStudy: Feasibility Trial for a Right Ven
 tricular Failure Platform Trial\nEstimated primary completion: 31 March 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/ranolazine#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06570473
URL:https://assetmemo.bio/drug/ranolazine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06527222-8659@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Ranolazine: Phase 2 readout est. (NCT06527222)
DESCRIPTION:Ranolazine\, phase 2.\nStudy: A Study of Ranolazine in ALS\nEst
 imated primary completion: July 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/ranolazine#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06527222
URL:https://assetmemo.bio/drug/ranolazine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
